The present invention relates to a batch crystallization method for
crystallizing anti-human TNFalpha (hTNFalpha) antibody and antibody
fragments which allows the production of said antibody on an industrial
scale; a method of controlling the size of antibody crystals, for
example, crystals of anti-hTNFalpha antibody fragments, compositions
containing said crystals as well as methods of use of said crystals and
compositions.